THE DIAGNOSTIC VALUE OF PLATELET-DERIVED FACTOR PDGF-BB AND ST2 IN HEART REJECTION

Aim: to determine the association between plasma concentrations of biomarkers (sCD40L, PDGF-BB, PlGF-1, ST2) with histochemical and immunohistochemical signs of heart rejection.

Materials and methods. The study included 98 heart recipients aged from 12 to 69 (mean age 43 ± 14) years, of which 78 men. In 68 patients dilated cardiomyopathy was diagnosed, 30 recipients were diagnosed with coronary heart disease. The concentrations of placental growth factor (PlGF-1), platelet-derived growth factor (PDGF-BB), soluble CD40 ligand (sCD40L) were measured using xMAP technology. The concentrations of ST2 cardiac biomarker were measured by ELISA.

Results. No correlation was found between the levels of biomarkers (sCD40L, PDGF-BB, PlGF-1, ST2) and gender, age and diagnosis. The rejection was diagnosed via biopsy in 49 biopsies taken from 37 recipients. 1A rejection was found in 25 patients (34 biopsies), 1B rejection was identifi ed in 2 patients (3 biopsies), 3A rejection was diagnosed in 4 patients. Immunohistochemical signs of humoral rejection were identifi ed in 3 patients. The combination of acute cellular and humoral rejection was found in 4 patients (5 biopsies). The PDGFBB level was measured at the same day as the biopsy was taken, and it was shown to be signifi cantly higher in patients with rejection (p = 0.02). Rejection frequency was signifi cantly higher in patients with high PDGF-BB level (≥2473.7 pg/ml, RR = 1.64 ± 0.23; 95% CI [1.03–2.61]). Rejection frequency increased to 2.11 ± 0.34 [95% CI [1.08–4.11]] in recipients with ST2 and PDGF-BB concentration higher than the median value. The highest predictive value for heart rejection can be reached by a panel of three biomarkers: sCD40L, PlGF-1 and ST2 (RR = 2.51 ± 0.38; 95% CI [1.18–5.3]).

Conclusion. PDGF-BB has moderate predictive value for heart rejection. The highest predictive value for heart rejection was reached by a panel of three biomarkers: sCD40L, PlGF-1 and ST2.

1. Готье СВ, Шевченко АО, Попцов ВН. Пациент с трансплантированным сердцем: Руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. М.: Тверь: Триада, 2014. 144. Gautier SV, Shevchenko AO, Poptsov VN. Patsient s transplantirovannym serdtsem: Rukovodstvo dlya vrachey po vedeniyu patsientov, perenesshikh trasnplantatsiyu serdtsa. M.: Tver’: Triada, 2014. 144.

2. Космачева ЕД, Кижватова НВ, Гордеева ЕВ и др. Осложнения в послеоперационном периоде у пациентов, перенесших ортоптическую трансплантацию сердца. Клиническая медицина. 2014; 92 (4): 30–34. Kosmacheva ED, Kizhvatova NV, Gordeeva EV i dr. Oslozhneniya v posleoperatsionnom periode u patsientov, perenesshikh ortopticheskuyu transplantatsiyu serdtsa. Klinicheskaya meditsina. 2014; 92 (4): 30–34.

3. Frick M, Antretter H, Pachinger O, Pölzl G. Biomarker for diagnosis of rejection after heart transplantation. Herz. 2010; 35 (1): 11–16.

4. Насырова АА, Шевченко АО. Функциональные показатели магистральных артерий и риск отторжения трансплантированного сердца. Трансплантология: итоги и перспективы. Том VII. 2015 год. Под ред. С.В. Готье. М. Тверь: Триада, 2016: 331–350. Nasyrova AA, Shevchenko AO. Funktsional’nye pokazateli magistral’nykh arteriy i risk ottorzheniya transplantirovannogo serdtsa. Transplantologiya: itogi i perspektivy. Tom VII. 2015 god. Pod red. SV Gautier. M. Tver’: Triada, 2016: 331–350.

5. Yusen RD, Edwards LB, Kucheryava AY et al. The Registry of International Society for Heart and Lung Transplantation: Thirty-second Offi cial Adult Heart Transplantation Report. The Journal of Heart and Lung Transplantation. 2015. 34: 1264–1277.

6. Martinez-Dolz L, Almenar L, Reganon E. et al. What is the best biomarker for diagnosis of rejection in heart transplantation? Clinical Transplantation. 2009; 23: 672– 680.

7. Стаханова ЕА, Шевченко ОП. Роль мультиплексного анализа биомаркеров неоангиогенеза и воспаления при трансплантации сердца. Трансплантология: итоги и перспективы. Том VII. 2015 год. Под редакцией С.В. Готье. М. Тверь: Триада, 2016: 422–442. Stakhanova EA, Shevchenko OP. Rol’ mul’tipleksnogo analiza biomarkerov neoangiogeneza i vospaleniya pri transplantatsii serdtsa. Transplantologiya: itogi i perspektivy. Tom VII. 2015 god. Pod redaktsiey SV Gautier. M. Tver’: Triada, 2016: 422–442.

8. Kennel PJ, Schulze PC. Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation. Current Heart Failure Reports. 2015 Oct; 12 (5): 328– 332. doi: 10.1007/s11897-015-0269-1.

9. Sack FU, Vielfort TJ, Koch A. et al. The role of platelet derived growth factor in endomyocardial biopsies shortly after heart transplantation in relation to postoperative course. European Journal Cardiothoracic Surgery. 2004; 25 (1): 91–97.

10. Lee GY, Choi JO, Ju ES, Lee YJ, Jeon ES. Role of Soluble ST2 as a Marker for Rejection after Heart Transplant. Korean Circ. J. 2016 Nov; 46 (6): 811–820. doi: 10.4070/kcj.2016.46.6.811.

11. Dengler TJ, Gleissner CA, Klingenberg R et al. Biomarkers after heart transplantation: nongenomic. Heart Failure Clin. 2007 Jan; 3 (1): 69–81.

12. Долгов ВВ, Шевченко ОП, Шевченко АО. Биомаркеры в лабораторной диагностике. М. Тверь: Триада, 2014. 288. Dolgov VV, Shevchenko OP, Shevchenko AO. Biomarkery v laboratornoy diagnostike. M. Tver’: Triada, 2014. 288.

13. Breen EJ, Polaskova V, Khan A. Bead-based multiplex immune-assays for cytokines, chemokines, growth factors and other analytes: median fl uorescence intensities versus their derived absolute concentration values for statistical analysis. Cytokine. 2015; 71 (2): 188–198.

14. Biancotto A, Wank A, Perl S. et al. Baseline levels and temporal stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PLoS One. 2013; 8 (12): e76091.